|D018754||Ventricular Dysfunction NIH||0.58|
|D018487||Ventricular Dysfunction, Left NIH||0.58|
|D006976||Hypertension, Pulmonary NIH||0.50|
There is one clinical trial.
Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients infected with COVID-19.
Description: All cause deathMeasure: Mortality Time: 30 days
Description: Prevalence of left ventricular dysfunctionMeasure: Left ventricular dysfunction Time: Within 72 hours from admission
Description: Prevalence of right ventricular dysfunctionMeasure: Right ventricular dysfunction Time: Within 72 hours from admission
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports